JP2020096620A - 自己免疫および多発性硬化症の処置 - Google Patents
自己免疫および多発性硬化症の処置 Download PDFInfo
- Publication number
- JP2020096620A JP2020096620A JP2020020901A JP2020020901A JP2020096620A JP 2020096620 A JP2020096620 A JP 2020096620A JP 2020020901 A JP2020020901 A JP 2020020901A JP 2020020901 A JP2020020901 A JP 2020020901A JP 2020096620 A JP2020096620 A JP 2020096620A
- Authority
- JP
- Japan
- Prior art keywords
- subject
- fmd
- fasting
- less
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000005784 autoimmunity Effects 0.000 title abstract description 5
- 201000006417 multiple sclerosis Diseases 0.000 title description 39
- 238000011282 treatment Methods 0.000 title description 15
- 230000001363 autoimmune Effects 0.000 claims abstract description 26
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 24
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 235000019577 caloric intake Nutrition 0.000 claims abstract description 21
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 20
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 20
- 208000024891 symptom Diseases 0.000 claims abstract description 20
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 19
- 235000000346 sugar Nutrition 0.000 claims abstract description 14
- 150000001413 amino acids Chemical class 0.000 claims abstract description 13
- 230000008929 regeneration Effects 0.000 claims abstract description 12
- 238000011069 regeneration method Methods 0.000 claims abstract description 12
- 235000020925 non fasting Nutrition 0.000 claims abstract description 7
- 230000001737 promoting effect Effects 0.000 claims abstract description 7
- 235000013410 fast food Nutrition 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 abstract description 32
- 230000037213 diet Effects 0.000 abstract description 29
- 235000021439 fasting mimicking diet Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 description 32
- 210000001744 T-lymphocyte Anatomy 0.000 description 28
- 235000013305 food Nutrition 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 108090000695 Cytokines Proteins 0.000 description 17
- 102000004127 Cytokines Human genes 0.000 description 17
- 235000020887 ketogenic diet Nutrition 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 13
- 210000004248 oligodendroglia Anatomy 0.000 description 13
- 235000012054 meals Nutrition 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- 235000021003 saturated fats Nutrition 0.000 description 10
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 9
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 9
- 235000021084 monounsaturated fats Nutrition 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 235000021085 polyunsaturated fats Nutrition 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 208000037976 chronic inflammation Diseases 0.000 description 5
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 235000021236 calorie-restricted diet Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000004626 essential fatty acids Nutrition 0.000 description 4
- 230000037219 healthy weight Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000011785 micronutrient Substances 0.000 description 4
- 235000013369 micronutrients Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 210000000535 oligodendrocyte precursor cell Anatomy 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 235000000891 standard diet Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 2
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920003354 Modic® Polymers 0.000 description 2
- 101100273001 Mus musculus Cacna1s gene Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000020934 caloric restriction Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000020053 Abnormal inflammatory response Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101001081567 Homo sapiens Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 102100027636 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 1
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 235000019787 caloric expenditure Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021097 low calorie intake Nutrition 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Abstract
Description
本出願は、2014年4月2日出願の米国仮特許出願第61/974,189号明細書の利益を主張する。この開示は、その全体が引用を以って本明細書中に組み込まれる。
本発明は、国立衛生研究所(National Institutes of Health)/国立老化研究所(National Institute of Aging)によって授与された契約番号PO1AGT034906の下に、政府支援を受けてなされた。政府は、本発明に対して、一定の権利を有する。
「AL」はアドリブを意味する。
「DAPI」は、蛍光染色である4’,6−ジアミジノ−2−フェニルインドールを意味する。
「EAE」は、実験的自己免疫性脳脊髄炎を意味する。
「FMD」は、断食もどき食を意味する。
「KB」は、ケトン体を意味する。
「KD」は、ケトジェニック食を意味する。
「MOG35〜55」は、ミエリン乏突起膠細胞糖タンパク質を意味する。
「MS」は、多発性硬化症を意味する。
「STZ」は、ストレプトゾトシンを意味する。
Claims (1)
- 自己免疫疾患または炎症性疾患を有する対象における自己免疫または炎症性疾患の症候を軽減する一方で再生を促進するためのキットにおいて、
第1の所定期間、前記対象に提供する断食もどき食であって、100グラム未満の炭水化物を、1日あたり30g未満の糖および1日あたり 28g未満のタンパク質/アミノ酸と共に提供する断食もどき食と、
前記第1の所定期間に続いて第2の所定期間、前記対象に投与する非断食食であって、標準的なカロリー摂取量を提供する非断食食と、
を具えることを特徴とするキット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461974189P | 2014-04-02 | 2014-04-02 | |
US61/974,189 | 2014-04-02 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016559645A Division JP6727130B2 (ja) | 2014-04-02 | 2015-04-02 | 自己免疫および多発性硬化症の処置 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020096620A true JP2020096620A (ja) | 2020-06-25 |
JP2020096620A5 JP2020096620A5 (ja) | 2021-05-20 |
JP7021794B2 JP7021794B2 (ja) | 2022-02-17 |
Family
ID=54241439
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016559645A Active JP6727130B2 (ja) | 2014-04-02 | 2015-04-02 | 自己免疫および多発性硬化症の処置 |
JP2020020901A Active JP7021794B2 (ja) | 2014-04-02 | 2020-02-10 | 自己免疫および多発性硬化症の処置 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016559645A Active JP6727130B2 (ja) | 2014-04-02 | 2015-04-02 | 自己免疫および多発性硬化症の処置 |
Country Status (10)
Country | Link |
---|---|
US (1) | US11406122B2 (ja) |
EP (1) | EP3125904A4 (ja) |
JP (2) | JP6727130B2 (ja) |
KR (1) | KR20170003542A (ja) |
CN (1) | CN107613989A (ja) |
AU (1) | AU2015240720B2 (ja) |
CA (1) | CA2944479C (ja) |
MX (1) | MX2016012896A (ja) |
RU (1) | RU2687750C2 (ja) |
WO (1) | WO2015153850A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2687750C2 (ru) | 2014-04-02 | 2019-05-16 | Юниверсити Оф Саутерн Калифорния | Лечение аутоиммунной реакции и рассеянного склероза |
BR112017023748A2 (pt) * | 2015-05-06 | 2018-07-31 | University Of Southern California | métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso |
JP2019505592A (ja) * | 2016-02-15 | 2019-02-28 | ユニバーシティ オブ サザン カリフォルニア | 糖尿病及び他の疾患を治療するための胚様再生を刺激するための薬剤の組み合わせ及び方法 |
AU2017261723B2 (en) * | 2016-05-11 | 2023-02-09 | University Of Southern California | Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases. |
US11284640B2 (en) * | 2017-02-14 | 2022-03-29 | University Of Southern California | Fasting mimicking diet |
US20190075834A1 (en) * | 2017-09-12 | 2019-03-14 | Nestec Sa | Methods for mimicking chronic caloric restriction and for imparting health benefits to an animal |
KR20200125966A (ko) | 2018-03-15 | 2020-11-05 | 유니버시티 오브 써던 캘리포니아 | 염증 및 ibd 병리의 역전을 촉진하는, 물만 섭취하는 금식이 아닌 금식 모방 식이요법 (fmd) |
KR102216752B1 (ko) * | 2019-06-03 | 2021-02-17 | 국제뇌교육종합대학원대학교 산학협력단 | 황칠나무 추출물을 포함하는 탈수초 질환의 예방 또는 치료용 조성물 |
GB201918657D0 (en) | 2019-12-17 | 2020-01-29 | Tdeltas Ltd | Compounds for new use |
IT202000016957A1 (it) * | 2020-07-13 | 2022-01-13 | Univ Degli Studi Di Palermo | Composizione dietetica per il trattamento della depressione |
US20220175007A1 (en) * | 2020-12-09 | 2022-06-09 | University Of Southern California | Fasting mimicking ketogenic diet to improve immune function and vaccine response and minimize risk in adults and elderly |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040121044A1 (en) * | 2001-03-14 | 2004-06-24 | John Tiano | Nutritional product with high protein, low carbohydrate content and good physical stability |
US20060252775A1 (en) * | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
WO2008119077A1 (en) | 2007-03-28 | 2008-10-02 | University Of Southern California | Induction of differential stress resistance and uses thereof |
US8865646B2 (en) | 2007-03-28 | 2014-10-21 | University Of South California | Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging |
WO2011050302A2 (en) * | 2009-10-22 | 2011-04-28 | University Of Southern California | Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment |
ES2555032T3 (es) * | 2010-01-19 | 2015-12-28 | Mjn U.S. Holdings Llc | Compensación nutricional para dieta de tipo occidental |
EP2563398B1 (en) | 2010-04-28 | 2017-04-19 | University of Southern California | Growth hormone receptor deficiency causes a major reduction in pro-aging signaling, cancer and diabetes in humans |
WO2012109353A2 (en) | 2011-02-08 | 2012-08-16 | University Of Southern California | Growth hormone receptor deficiency causes a major reduction in pro-aging signaling, cancer and diabetes in humans |
CA2844811A1 (en) * | 2011-08-19 | 2013-02-28 | European Ketogenic Weight Loss Clinics Llc | Methods for weight loss and ketogenic compositions |
ES2822178T3 (es) * | 2012-10-22 | 2021-04-29 | Univ Southern California | Formulaciones dietéticas que promueven la regeneración de tejidos/órganos |
MX2015010320A (es) | 2013-02-12 | 2016-06-02 | Univ Southern California | Metodos y dietas para proteger contra la quimiotoxicidad y enfermedades asociadas con la edad. |
BR112015024186B1 (pt) * | 2013-03-19 | 2023-05-09 | University Of South Florida | Composições e métodos para produção de cetose de elevação e manutenção |
RU2672594C2 (ru) | 2013-07-01 | 2018-11-16 | Юниверсити Оф Саутерн Калифорния | Состояние воздержания от пищи в качестве диетического лечения диабета |
US10172839B2 (en) | 2014-03-06 | 2019-01-08 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
RU2687750C2 (ru) | 2014-04-02 | 2019-05-16 | Юниверсити Оф Саутерн Калифорния | Лечение аутоиммунной реакции и рассеянного склероза |
-
2015
- 2015-04-02 RU RU2016140158A patent/RU2687750C2/ru active
- 2015-04-02 MX MX2016012896A patent/MX2016012896A/es unknown
- 2015-04-02 AU AU2015240720A patent/AU2015240720B2/en active Active
- 2015-04-02 KR KR1020167030224A patent/KR20170003542A/ko not_active Application Discontinuation
- 2015-04-02 CN CN201580028222.7A patent/CN107613989A/zh active Pending
- 2015-04-02 EP EP15774032.5A patent/EP3125904A4/en active Pending
- 2015-04-02 CA CA2944479A patent/CA2944479C/en active Active
- 2015-04-02 WO PCT/US2015/024021 patent/WO2015153850A2/en active Application Filing
- 2015-04-02 US US15/301,480 patent/US11406122B2/en active Active
- 2015-04-02 JP JP2016559645A patent/JP6727130B2/ja active Active
-
2020
- 2020-02-10 JP JP2020020901A patent/JP7021794B2/ja active Active
Non-Patent Citations (1)
Title |
---|
ANTIOXIDANTS AND REDOX SIGNALING, vol. 19, no. 18, JPN6019005106, 20 December 2013 (2013-12-20), pages 2286 - 2334, ISSN: 0004489330 * |
Also Published As
Publication number | Publication date |
---|---|
EP3125904A2 (en) | 2017-02-08 |
CA2944479A1 (en) | 2015-10-08 |
JP7021794B2 (ja) | 2022-02-17 |
JP2017515458A (ja) | 2017-06-15 |
AU2015240720A1 (en) | 2016-10-20 |
US11406122B2 (en) | 2022-08-09 |
US20170027217A1 (en) | 2017-02-02 |
KR20170003542A (ko) | 2017-01-09 |
RU2016140158A (ru) | 2018-05-04 |
JP6727130B2 (ja) | 2020-07-22 |
MX2016012896A (es) | 2017-05-12 |
AU2015240720B2 (en) | 2019-12-05 |
CA2944479C (en) | 2023-02-21 |
WO2015153850A2 (en) | 2015-10-08 |
RU2687750C2 (ru) | 2019-05-16 |
RU2016140158A3 (ja) | 2018-10-25 |
EP3125904A4 (en) | 2017-08-30 |
CN107613989A (zh) | 2018-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020096620A (ja) | 自己免疫および多発性硬化症の処置 | |
Rondanelli et al. | Focus on metabolic and nutritional correlates of polycystic ovary syndrome and update on nutritional management of these critical phenomena | |
DeBoer | Use of ghrelin as a treatment for inflammatory bowel disease: mechanistic considerations | |
CN108095123A (zh) | 一种缓解压力的营养组合物及其制备方法与应用 | |
Stamler et al. | Relation of food and nutrient intakes to body mass in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial | |
JP2018537091A (ja) | 中鎖トリグリセリド組成物 | |
Almutairi et al. | Clinical implications of intermittent Ramadan fasting on stable plaque psoriasis: a prospective observational study | |
EP2880993A1 (en) | Method of achieving memory and learning improvement by the administration of sialic acid | |
EP3789023A1 (en) | Composition for preventing or treating cognitive disorder-associated diseases, containing mumefural | |
US20090099259A1 (en) | Method for regulating gene expression | |
Prasad | Zinc in human health | |
US6833142B2 (en) | Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions | |
JP2014187997A (ja) | 抗老化食品 | |
Tahilani et al. | Current scenario of nutraceuticals and food fortification in India | |
Westoby et al. | P069 Ultra-processed food intake and dietary insufficiencies are common in adults with Crohn’s Disease in remission. The INTICO 2 Study | |
Ebrahimi Meimand et al. | Evaluation of fasting effects during the Holy month of Ramadan on patients with epileptic attacks who visited the Emergency Room | |
Giampapa | Every man takes the limits of his own field of vision for the limits of the world. | |
Class et al. | Patent application title: Methods and Compositions for Slowing an Aging Process in a Human or an Animal Inventors: Luke Blotsky (Goodyear, AZ, US) Krys Bojanowski (Goodyear, AZ, US) Assignees: Core Intellectual Properties Holdings, LLC | |
Galali et al. | The impact of ketogenic diet on some metabolic and non‐metabolic diseases: Evidence from human and animal model experiments | |
WO2023067203A2 (en) | Food additives | |
Repaci et al. | Mariangela Rondanelli, Simone Perna, Milena Faliva, Francesca Monteferrario | |
Herber et al. | Effects of Aging on Skeletal Muscle Hypertrophy | |
Doss | Developments in the Fight against Cancer Cachexia | |
Cochran et al. | Cetyl Myristoleate-A Unique Natural Compound Valuable in Arthritis Conditions | |
Thomas | Are older people starving to death in a world of plenty? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200311 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210408 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210420 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210720 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220104 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220128 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7021794 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |